

CHANGE - ANNOUNCEMENT OF CESSATION::CESSATION OF NIR GOLDENBERG, CEO TRENDLINES INNOVATION LABS**Issuer & Securities****Issuer/ Manager**

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No

Announcement Details**Announcement Title**

Change - Announcement of Cessation

Date &Time of Broadcast

02-Aug-2022 19:53:57

Status

New

Announcement Sub Title

Cessation of Nir Goldenberg, CEO Trendlines Innovation Labs

Announcement Reference

SG220802OTHR4UBB

Submitted By (Co./ Ind. Name)

Haim Brosh

Designation

Joint Company Secretary

Description (Please provide a detailed description of the event in the box below)

This announcement has been reviewed by the Company s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the Sponsor). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the Exchange) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

Additional Details

<p>Name Of Person</p> <p>Nir Goldenberg</p>
<p>Age</p> <p>39</p>
<p>Is effective date of cessation known?</p> <p>Yes</p>
<p>If yes, please provide the date</p> <p>21/08/2022</p>
<p>Detailed Reason (s) for cessation</p> <p>Nir Goldenberg tendered his resignation to pursue other career opportunities abroad and is currently serving his notice period.</p> <p>Based on its inquiries, the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. is satisfied that other than as disclosed in this announcement, there are no other material reasons for the cessation of Nir Goldenberg as CEO of Trendlines Innovation Labs.</p>
<p>Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?</p> <p>No</p>
<p>Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?</p> <p>No</p>
<p>Any other relevant information to be provided to shareholders of the listed issuer?</p> <p>No</p>
<p>Date of Appointment to current position</p> <p>01/02/2019</p>
<p>Does the AC have a minimum of 3 members (taking into account this cessation)?</p> <p>Yes</p>
<p>Number of Independent Directors currently resident in Singapore (taking into account this cessation)</p> <p>2</p>
<p>Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months</p> <p>1</p>
<p>Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)</p> <p>CEO of Trendlines Innovation Labs</p>
<p>Role and responsibilities</p> <p>Responsible for the overall management of Trendlines Innovation Labs</p>
<p>Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal</p>

subsidiaries No
Shareholding interest in the listed issuer and its subsidiaries? Yes
Shareholding Details 5176753 unexercised options of which 2,323,973 are vested.
Past (for the last 5 years) Hyblate Medical Ltd.
Present Nil